ProAir® HFA (albuterol) – First-time generic

- On January 17, 2019, Teva launched an authorized generic version of ProAir HFA (albuterol) inhalation aerosol.
  - Teva Respiratory also markets the branded version of ProAir HFA.

- ProAir HFA is approved for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients aged 4 years and older.

- Albuterol is also available generically as oral tablets, oral extended-release tablets, oral syrup, inhalation nebulizer solution, inhalation aerosol and combination ipratropium/albuterol inhalation solution, and as a branded inhalation aerosol (Proventil® HFA) and inhalation powder (ProAir Respliclick®).
  - Albuterol tablets and extended-release tablets are approved for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
  - Albuterol syrup is approved for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease.
  - Albuterol nebulizer solution is approved for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
  - Ipratropium/albuterol is approved for the treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients requiring more than one bronchodilator.
  - Generic inhalation aerosol, Proventil HFA and ProAir Respliclick carry the same indications as ProAir HFA.